WINTON GROUP Ltd trimmed its stake in shares of Pfizer Inc. (NYSE:PFE) by 23.2% during the 2nd quarter, Holdings Channel reports. The fund owned 28,205 shares of the biopharmaceutical company’s stock after selling 8,506 shares during the quarter. WINTON GROUP Ltd’s holdings in Pfizer were worth $1,023,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Laurel Wealth Advisors Inc. grew its position in shares of Pfizer by 9.5% in the 2nd quarter. Laurel Wealth Advisors Inc. now owns 65,964 shares of the biopharmaceutical company’s stock worth $2,393,000 after buying an additional 5,718 shares during the last quarter. Nomura Holdings Inc. grew its position in shares of Pfizer by 123.5% in the 2nd quarter. Nomura Holdings Inc. now owns 541,074 shares of the biopharmaceutical company’s stock worth $19,630,000 after buying an additional 299,022 shares during the last quarter. M Holdings Securities Inc. grew its position in shares of Pfizer by 11.9% in the 2nd quarter. M Holdings Securities Inc. now owns 28,495 shares of the biopharmaceutical company’s stock worth $1,034,000 after buying an additional 3,031 shares during the last quarter. Carnegie Capital Asset Management LLC grew its position in shares of Pfizer by 6.8% in the 2nd quarter. Carnegie Capital Asset Management LLC now owns 122,007 shares of the biopharmaceutical company’s stock worth $4,967,000 after buying an additional 7,778 shares during the last quarter. Finally, Amussen Hunsaker Associates LLC boosted its position in shares of Pfizer by 21.3% during the second quarter. Amussen Hunsaker Associates LLC now owns 10,746 shares of the biopharmaceutical company’s stock valued at $390,000 after purchasing an additional 1,886 shares in the last quarter. Institutional investors and hedge funds own 69.42% of the company’s stock.
Several equities research analysts recently weighed in on PFE shares. Cantor Fitzgerald set a $45.00 price target on Pfizer and gave the company a “buy” rating in a research report on Thursday, October 4th. Morgan Stanley set a $45.00 price target on Pfizer and gave the company a “buy” rating in a research report on Wednesday, August 29th. Goldman Sachs Group restated a “neutral” rating and set a $45.00 price target on shares of Pfizer in a research report on Tuesday, October 30th. Independent Research set a $48.00 price target on Pfizer and gave the company a “neutral” rating in a research report on Thursday, October 4th. Finally, Credit Suisse Group set a $40.00 price target on Pfizer and gave the company a “hold” rating in a research report on Thursday, September 6th. Two investment analysts have rated the stock with a sell rating, fifteen have given a hold rating and nine have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $43.27.
Shares of NYSE:PFE opened at $43.92 on Friday. The firm has a market cap of $267.76 billion, a price-to-earnings ratio of 16.57, a P/E/G ratio of 2.24 and a beta of 0.88. Pfizer Inc. has a 12-month low of $33.20 and a 12-month high of $46.47. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.43 and a quick ratio of 1.15.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 30th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.75 by $0.03. The business had revenue of $13.30 billion during the quarter, compared to analysts’ expectations of $13.53 billion. Pfizer had a return on equity of 25.26% and a net margin of 44.63%. The firm’s quarterly revenue was up 1.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.67 earnings per share. As a group, research analysts anticipate that Pfizer Inc. will post 3 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Monday, December 3rd. Shareholders of record on Friday, November 9th were paid a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a yield of 3.10%. The ex-dividend date was Thursday, November 8th. Pfizer’s payout ratio is 51.32%.
COPYRIGHT VIOLATION WARNING: This piece was published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.chaffeybreeze.com/2018/12/08/winton-group-ltd-sells-8506-shares-of-pfizer-inc-pfe.html.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Read More: What is the S&P 500 Index?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.